Video Experimental Relacionado

Updated: May 3, 2026

The Use of Fluorescent Target Arrays for Assessment of T Cell Responses In vivo

The Use of Fluorescent Target Arrays for Assessment of T Cell Responses In vivo

Published on: June 19, 2014

Respuesta duradera a glofitamab en linfoma de Burkitt refractario positivo para VIH: reporte de caso y discusión

Bozzotto Elisa¹, Magnes Theresa¹, Kiem Dominik¹

¹Department of Internal Medicine III With Hematology, Medical Oncology, Hemostaseology, Infectiology, and Rheumatology Paracelsus Medical University University Clinic Salzburg Salzburg Austria.

|February 16, 2026

Abstracto

Background:

Refractory Burkitt lymphoma (BL) has a dismal prognosis after failure of frontline therapy. New treatment options are urgently needed.

Methods:

We describe a 60-year-old HIV-positive patient with refractory and secondary primary BL after frontline and salvage therapy failure, treated off-label with glofitamab successfully.

Results:

Twelve cycles of glofitamab were well tolerated and led to complete metabolic remission confirmed by imaging and biopsy, sustained for nine months post-treatment.

Conclusion:

Glofitamab may represent a promising stand-alone option in relapsed BL, when conventional cytotoxic therapies are exhausted. Clinical Trial Registration: The authors have confirmed that clinical trial registration is not needed for this submission.

Palabras clave:

linfoma de Burkitt VIH anticuerpos biespecíficos glofitamab linfoma refractario terapia limitada en el tiempo

Más Videos Relacionados

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Videos de Conceptos Relacionados

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Pulmonary Tuberculosis III

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories: